Neurotoxicity continues to be a leading cause of clinical trial failure. In large part, this is attributed to a lack of clinically relevant in vitro models. The microBrain functional organoid platform offers high-throughput access to human-derived complex cultures of neurons and support cells. Testing strategies include acute and chronic exposures with single or repeat dosing strategies as well as functional, structural, cell viability, and transcriptomic endpoints to provide a holistic picture of compound impact on neural function.
Spontaneous neural activity in microBrain functional organoids
Adverse impacts on cell-specific function are often the earliest indication of compound induced toxicity. See how microBrain functional organoids provide accurate and reproducible data on neural function in complex 3D models.
IC50 of rotenone on microBrain 3D
Cell viability is the terminal toxicity endpoint and integral component of any toxicity assessment. We offer several readouts for cell health and viability that can be used in isolation or multiplexed with other assay endpoints.
High-content imaging is a key approach to understanding multiple toxicity endpoints. Our scientists employ a variety of imaging techniques to provide robust, quantitative, and actionable data.
Genetic and epigenetic changes typically underlie long-term and chronic toxicities. These changes are primarily assessed through focused or genome-wide expression analyses.